Page 2304 - Williams Hematology ( PDFDrive )

2278 Part XII: Hemostasis and Thrombosis Chapter 133: Venous Thrombosis 2279

39. Righini M, Van Es J, Den Exter PL, et al: Age-adjusted D-dimer cutoff levels to rule out 70. Kearon C, Ginsberg J, Kovacs M, et al: Comparison of low-intensity warfarin therapy
pulmonary embolism: The ADJUST-PE study. JAMA 311:1117, 2014. with conventional intensity warfarin therapy for long-term prevention of recurrent
40. Rathbun S, Whitsett T, Raskob G: Sensitivity and specificity of helical computed tomog- venous thromboembolism. N Engl J Med 349:631, 2003.
raphy in the diagnosis of pulmonary embolism: A systematic review. Ann Intern Med 71. Crowther M, Ginsberg J, Julian J, et al: A comparison of two intensities of warfarin for
132:227, 2000. the prevention of recurrent thrombosis in patients with the antiphospholipid antibody
41. Patel S, Kazerooni EA, Cascade PN: Pulmonary embolism: Optimization of small syndrome. N Engl J Med 349:1133, 2003.
pulmonary artery visualization at multi-detector row CT. Radiology 227:455, 2003. 72. Hull R, Hirsh J, Jay R, et al: Different intensities of oral anticoagulant therapy in the
42. Perrier A, Roy PM, Sanchez O, et al: Multi-detector row computed tomography in treatment of proximal-vein thrombosis. N Engl J Med 307:1676, 1982.
suspected pulmonary embolism. N Engl J Med 352:1760, 2005. 73. Schulman S, Kearon C, Kakkar A, et al: Dabigatran versus warfarin in the treatment of
43. Stein PD, Fowler SE, Goodman LR, et al: Multi-detector computed tomography for acute venous thromboembolism. N Engl J Med 361:2342, 2009.
acute pulmonary embolism. N Engl J Med 354:2317, 2006. 74. Schulman S, Kakkar AK, Goldhaber SZ, et al: Treatment of acute venous thromboem-
44. van Belle A, Büller HR, Huisman MV, et al: Effectiveness of managing suspected bolism with dabigatran or warfarin and pooled analysis. Circulation 129:764, 2014.
pulmonary embolism using an algorithm combining clinical probability, D-dimer test- 75. EINSTEIN Investigators, Bauersachs R, Berkowitz SD, et al: Oral rivaroxaban for symp-
ing, and computed tomography. JAMA 295:172, 2006. tomatic venous thromboembolism. N Engl J Med 363:2499, 2010.
45. Hull R, Raskob G, Coates G, Panju A: Clinical validity of a normal perfusion lung scan 76. EINSTEIN-PE Investigators, Büller HR, Prins MH, et al: Oral rivaroxaban for the treat-
in patients with suspected pulmonary embolism. Chest 97:23, 1990. ment of symptomatic pulmonary embolism. N Engl J Med 366:1287, 2012.
46. Miniati M, Prediletto A, Fornichi B, et al: Accuracy of clinical assessment in the diag- 77. Agnelli G, Buller H, Cohen A, et al: Oral apixaban for the treatment of acute venous
nosis of pulmonary embolism. Am J Respir Crit Care Med 159:864, 1999. thromboembolism. N Engl J Med 369:799, 2013.
47. Hull RD, Raskob GE, Ginsberg JS, et al: A noninvasive strategy for the treatment of 78. Hokusai-VTE Investigators, Büller HR, Décousus H, et al: Edoxaban versus warfarin for
patients with suspected pulmonary embolism. Arch Intern Med 154:289, 1994. the treatment of symptomatic venous thromboembolism. N Engl J Med 369:1406, 2013.
48. Anderson DR, Kahn SR, Rodger MA, et al: Computed tomographic pulmonary angi- 79. van Es N, Coppens M, Schulman S, et al: Direct oral anticoagulants compared with vita-
ography vs ventilation-perfusion lung scanning in patients with suspected pulmonary min K antagonists for acute symptomatic venous thromboembolism: Evidence from
embolism: A randomized controlled trial. JAMA 298:2743, 2007. phase 3 trials. Blood 124:1968, 2014.
49. Stein PD, Chenevert TL, Fowler SE, et al: Gadolinium-enhanced magnetic resonance 80. Kearon C, Akl E: Duration of anticoagulant therapy for deep vein thrombosis and
angiography for pulmonary embolism: A multicenter prospective study (PIOPED III). pulmonary embolism. Blood 123:1794, 2014.
Ann Intern Med 152:434, 2010. 81. Schulman S, Rhedin A-S, Lindmarker P, et al: A comparison of six weeks with six
50. van Strijen M, de Monye W, Schiereck J, et al: Single-detector helical computed tomog- months of oral anticoagulant therapy after a first episode of venous thromboembolism.
raphy as the primary diagnostic test in suspected pulmonary embolism: A multicenter N Engl J Med 332:1661, 1995.
clinical management study of 510 patients. Ann Intern Med 138:307, 2003. 82. Levine M, Hirsh J, Gent M, et al: Optimal duration of oral anticoagulant therapy: A
51. Hull R, Delmore T, Genton E, et al: Warfarin sodium versus low-dose heparin in the randomized trial comparing four weeks with three months of warfarin in patients with
long-term treatment of venous thrombosis. N Engl J Med 301:855, 1979. proximal deep-vein thrombosis. Thromb Haemost 74:606, 1995.
52. Prandoni P, Kahn S: Post-thrombotic syndrome: Prevalence, prognostication and need 83. Prandoni P, Lensing A, Prins M, et al: Residual venous thrombosis as a predictive factor
for progress. Br J Haematol 145:286, 2009. of recurrent venous thromboembolism. Ann Intern Med 137:955, 2002.
53. Prandoni P, Lensing AWA, Cogo A, et al: The long-term clinical course of acute deep 84. Palareti G, Cosmi B, Vigano D’Angelo S, et al: D-dimer testing to determine the dura-
venous thrombosis. Ann Intern Med 125:1, 1996. tion of anticoagulant therapy. N Engl J Med 355:1780, 2006.
54. Prandoni P, Lensing AW, Prins MH, et al: Below knee elastic compression stockings to 85. Kyrle P, Minar E, Bialonczyk, et al: The risk of recurrent venous thromboembolism in
prevent the post-thrombotic syndrome: A randomized controlled trial. Ann Intern Med men and women. N Engl J Med 350:2558, 2004.
141:249, 2004. 86. Palareti G, Cosmi B, Legnani C et al: D-dimer to guide the duration of anticoagulation
55. Kahn SR, Shapiro S, Wells PS, et al: SOX Trial Investigators: Compression stockings in patients with venous thromboembolism: A management study. Blood 124:196, 2014.
to prevent post-thrombotic syndrome: A randomized placebo-controlled trial. Lancet 87. Connors JM. Extended treatment of venous thromboembolism. N Engl J Med 368;
383:880, 2014. 767–769, 2013.
56. Pengo V, Lensing A, Prins M, et al: Incidence of chronic thromboembolic pulmonary 88. Schulman S, Kearon C, Kakkar A, et al: Extended use of dabigatran, warfarin, or
hypertension after pulmonary embolism. N Engl J Med 350:2257, 2004. placebo in venous thromboembolism. N Engl J Med 368:709, 2013.
57. Kearon C, Akl EA, Comerota A, et al: Antithrombotic therapy for VTE disease. Antith- 89. Agnelli G, Buller H, Cohen, et al: Apixaban for extended treatment of venous thrombo-
rombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest embolism. N Engl J Med 368:699, 2013.
Physicians Evidence-based Clinical Practice Guidelines. Chest 141 (2 Suppl):E419S, 90. Becattini C, Agnelli G, Schenone A, et al: Aspirin for preventing the recurrence of
2012. venous thromboembolism. N Engl J Med 366:1959, 2012.
58. Wells PS, Forgie MA, Rodger MA: Treatment of venous thromboembolism. JAMA 91. Brighton T, Eikelboom J, Mann K, et al: Low-dose aspirin for preventing recurrent
311:717, 2014. venous thromboembolism. N Engl J Med 367:1979, 2012.
59. Hull R, Raskob G, Hirsh J, et al: Continuous intravenous heparin compared with inter- 92. Schulman S, Granqvist S, Holmström M, et al: The duration of oral anticoagulant ther-
mittent subcutaneous heparin in the initial treatment of proximal vein thrombosis. apy after a second episode of venous thromboembolism. N Engl J Med 336:393, 1997.
N Engl J Med 315:1109, 1986. 93. Hull R, Pineo G, Brant R, et al: Self-managed long-term low-molecular-weight heparin
60. Brandjes D, Heijboer H, Buller H, et al: Acenocoumarol and heparin compared with therapy: The balance of benefits and harms. Am J Med 120:72, 2007.
acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl 94. Bates S, Greer IA, Middledorp S, et al: VTE, thrombophilia, antithrombotic therapy,
J Med 327:1485, 1992. and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: Ameri-
61. Lagerstedt C, Olsson C, Fagher B, et al: Need for long-term anticoagulant treatment in can College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141
symptomatic calf-vein thrombosis. Lancet 2:515, 1986. (2 Suppl):E691S, 2012.
62. Quinlan D, McQuillan A, Eikelboom J: Low-molecular-weight heparin compared with 95. Pettila V, Kaaja R, Leinonen P, et al: Thromboprophylaxis with low molecular weight
intravenous unfractionated heparin for treatment of pulmonary embolism. Ann Intern heparin (dalteparin) in pregnancy. Thromb Res 96:275, 1999.
Med 140:175, 2004. 96. Smith M, Norris L, Steer P, et al: Tinzaparin sodium for thrombosis treatment and pre-
63. Hull RD, Raskob GE, Brant RF, et al: Relation between the time to achieve the lower vention during pregnancy. Am J Obstet Gynecol 190:495, 2004.
limit of the APTT therapeutic range and recurrent venous thromboembolism during 97. Linkins L, Choi P, Douketis J: Clinical impact of bleeding in patients taking oral anti-
heparin treatment for deep vein thrombosis. Arch Intern Med 157:2562, 1997. coagulant therapy for venous thromboembolism. A meta-analysis. Ann Intern Med
64. Hull RD, Raskob GE, Brant RF, et al: The importance of initial heparin treatment on 139:893, 2003.
long-term clinical outcomes of antithrombotic therapy: The emerging theme of delayed 98. Goldhaber SZ, Haire WD, Feldstein ML, et al: Alteplase versus heparin in acute pulmo-
recurrence. Arch Intern Med 157:2317, 1997. nary embolism: Randomized trial assessing right-ventricular function and pulmonary
65. Buller H, Davidson B, Decousus H, et al: Fondaparinux or enoxaparin for the initial perfusion. Lancet 341:507, 1993.
treatment of symptomatic deep venous thrombosis. A randomized trial. Ann Intern 99. Meyer G, Vicaut E, Danays T et al: Fibrinolysis for patients with intermediate-risk
Med 140:867, 2004. pulmonary embolism. N Engl J Med 370:1402, 2014.
66. Matisse Investigators: Subcutaneous fondaparinux versus intravenous unfraction- 100. Enden T, Haig Y, Klow NE et al: CaVenT Study Group: Long-term outcome after addi-
ated heparin in the initial treatment of pulmonary embolism. N Engl J Med 349:1695, tional catheter-directed thrombolysis versus standard treatment for acute iliofemo-
2003. ral deep vein thrombosis (the CaVenT study): A randomized controlled trial. Lancet
67. Lee A, Levine M, Baker R, et al: Low-molecular-weight heparin versus Coumadin for 379:31, 2012.
the prevention of recurrent venous thromboembolism in patients with cancer. N Engl 101. Bashir R, Zack CJ, Zhao H, et al: Comparative outcomes of catheter-directed throm-
J Med 349:146, 2003. bolysis plus anticoagulation vs anticoagulation alone to treat lower-extremity proximal
68. Hull R, Pineo G, Brant R, et al: Long-term low-molecular-weight heparin versus usual deep vein thrombosis. JAMA Intern Med 174:1494, 2014.
care in proximal-vein thrombosis patients with cancer. Am J Med 119:1062, 2006. 102. Decousus H, Leizorovicz A, Parent F, et al: A clinical trial of vena caval filters in the
69. Ridker P, Goldhaber S, Danielson E, et al: Long-term low-intensity warfarin therapy for prevention of pulmonary embolism in patients with proximal deep-vein thrombosis.
the prevention of recurrent venous thromboembolism. N Engl J Med 348:1425, 2003. N Engl J Med 338:409, 1998.

Kaushansky_chapter 133_p2267-2280.indd 2279 9/18/15 10:53 AM